280 related articles for article (PubMed ID: 18189286)
1. Using peptides to study the interaction between the p53 tetramerization domain and HIV-1 Tat.
Gabizon R; Mor M; Rosenberg MM; Britan L; Hayouka Z; Kotler M; Shalev DE; Friedler A
Biopolymers; 2008; 90(2):105-16. PubMed ID: 18189286
[TBL] [Abstract][Full Text] [Related]
2. Protein transduction domains of HIV-1 and SIV TAT interact with charged lipid vesicles. Binding mechanism and thermodynamic analysis.
Ziegler A; Blatter XL; Seelig A; Seelig J
Biochemistry; 2003 Aug; 42(30):9185-94. PubMed ID: 12885253
[TBL] [Abstract][Full Text] [Related]
3. A novel approach to protein-protein interaction: complex formation between the p53 tumor suppressor and the HIV Tat proteins.
Longo F; Marchetti MA; Castagnoli L; Battaglia PA; Gigliani F
Biochem Biophys Res Commun; 1995 Jan; 206(1):326-34. PubMed ID: 7818536
[TBL] [Abstract][Full Text] [Related]
4. Probing the impact of valency on the routing of arginine-rich peptides into eukaryotic cells.
Kawamura KS; Sung M; Bolewska-Pedyczak E; Gariépy J
Biochemistry; 2006 Jan; 45(4):1116-27. PubMed ID: 16430208
[TBL] [Abstract][Full Text] [Related]
5. Functional cross-talk of HIV-1 Tat with p53 through its C-terminal domain.
Ariumi Y; Kaida A; Hatanaka M; Shimotohno K
Biochem Biophys Res Commun; 2001 Sep; 287(2):556-61. PubMed ID: 11554765
[TBL] [Abstract][Full Text] [Related]
6. Solvent-exposed residues located in the beta-sheet modulate the stability of the tetramerization domain of p53--a structural and combinatorial approach.
Mora P; Carbajo RJ; Pineda-Lucena A; Sánchez del Pino MM; Pérez-Payá E
Proteins; 2008 Jun; 71(4):1670-85. PubMed ID: 18076077
[TBL] [Abstract][Full Text] [Related]
7. Orientation and affinity of HIV-1 Tat fragments in Tat-TAR complex determined by fluorescence resonance energy transfer.
Cao H; Tamilarasu N; Rana TM
Bioconjug Chem; 2006; 17(2):352-8. PubMed ID: 16536465
[TBL] [Abstract][Full Text] [Related]
8. The interaction of HIV-1 Tat(32-72) with its target RNA: a fluorescence and nuclear magnetic resonance study.
Metzger AU; Bayer P; Willbold D; Hoffmann S; Frank RW; Goody RS; Rösch P
Biochem Biophys Res Commun; 1997 Dec; 241(1):31-6. PubMed ID: 9405229
[TBL] [Abstract][Full Text] [Related]
9. Latent and active p53 are identical in conformation.
Ayed A; Mulder FA; Yi GS; Lu Y; Kay LE; Arrowsmith CH
Nat Struct Biol; 2001 Sep; 8(9):756-60. PubMed ID: 11524676
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of HIV-1 Tat variants.
Pantano S; Carloni P
Proteins; 2005 Feb; 58(3):638-43. PubMed ID: 15609368
[TBL] [Abstract][Full Text] [Related]
11. Interactions of the HIV-1 Tat and RAP74 proteins with the RNA polymerase II CTD phosphatase FCP1.
Abbott KL; Archambault J; Xiao H; Nguyen BD; Roeder RG; Greenblatt J; Omichinski JG; Legault P
Biochemistry; 2005 Mar; 44(8):2716-31. PubMed ID: 15723517
[TBL] [Abstract][Full Text] [Related]
12. Structural and dynamic properties of the HIV-1 tat transduction domain in the free and heparin-bound states.
Hakansson S; Caffrey M
Biochemistry; 2003 Aug; 42(30):8999-9006. PubMed ID: 12885232
[TBL] [Abstract][Full Text] [Related]
13. Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function.
Lubin DJ; Butler JS; Loh SN
J Mol Biol; 2010 Jan; 395(4):705-16. PubMed ID: 19913028
[TBL] [Abstract][Full Text] [Related]
14. A fluorescence spectroscopy study on the interactions of the TAT-PTD peptide with model lipid membranes.
Tiriveedhi V; Butko P
Biochemistry; 2007 Mar; 46(12):3888-95. PubMed ID: 17338552
[TBL] [Abstract][Full Text] [Related]
15. Homonuclear (1)H-NMR assignment and structural characterization of human immunodeficiency virus type 1 Tat Mal protein.
Grégoire C; Péloponèse JM; Esquieu D; Opi S; Campbell G; Solomiac M; Lebrun E; Lebreton J; Loret EP
Biopolymers; 2001; 62(6):324-35. PubMed ID: 11857271
[TBL] [Abstract][Full Text] [Related]
16. The role of tetramerization in p53 function.
Chène P
Oncogene; 2001 May; 20(21):2611-7. PubMed ID: 11420672
[TBL] [Abstract][Full Text] [Related]
17. NMR studies of the phosphorylation motif of the HIV-1 protein Vpu bound to the F-box protein beta-TrCP.
Coadou G; Gharbi-Benarous J; Megy S; Bertho G; Evrard-Todeschi N; Segeral E; Benarous R; Girault JP
Biochemistry; 2003 Dec; 42(50):14741-51. PubMed ID: 14674748
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of the C-terminal sites of human p53 reduces non-sequence-specific DNA binding as modeled with synthetic peptides.
Hoffmann R; Craik DJ; Pierens G; Bolger RE; Otvos L
Biochemistry; 1998 Sep; 37(39):13755-64. PubMed ID: 9753464
[TBL] [Abstract][Full Text] [Related]
19. Selective side-chain modification of cysteine and arginine residues blocks pathogenic activity of HIV-1-Tat functional peptides.
Devadas K; Boykins RA; Hardegen NJ; Philp D; Kleinman HK; Osa EO; Wang J; Clouse KA; Wahl LM; Hewlett IK; Rappaport J; Yamada KM; Dhawan S
Peptides; 2006 Apr; 27(4):611-21. PubMed ID: 16256245
[TBL] [Abstract][Full Text] [Related]
20. The cationic cell-penetrating peptide CPP(TAT) derived from the HIV-1 protein TAT is rapidly transported into living fibroblasts: optical, biophysical, and metabolic evidence.
Ziegler A; Nervi P; Dürrenberger M; Seelig J
Biochemistry; 2005 Jan; 44(1):138-48. PubMed ID: 15628854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
